• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Factors associated with recanalization and reintervention following below knee polidocanol endovenous microfoam ablation for great saphenous and small saphenous veins.膝下聚多卡醇静脉内微泡沫消融治疗大隐静脉和小隐静脉后再通和再干预的相关因素。
J Vasc Surg Venous Lymphat Disord. 2024 Sep;12(5):101886. doi: 10.1016/j.jvsv.2024.101886. Epub 2024 Apr 3.
2
Endovenous microfoam ablation of below knee superficial truncal veins is safe and effective in patients with prior saphenous treatment across a wide range of CEAP classes.下肢浅静脉主干腔内微泡消融术治疗 CEAP 分级广泛的下肢浅静脉主干在既往大隐静脉处理后的患者中是安全且有效的。
J Vasc Surg Venous Lymphat Disord. 2022 Mar;10(2):390-394. doi: 10.1016/j.jvsv.2021.08.015. Epub 2021 Aug 30.
3
Increased body mass index and vein diameter are associated with incomplete target vein closure following microfoam ablation of incompetent saphenous veins.静脉内直径和体重指数增加与微泡沫消融治疗功能不全隐静脉后靶静脉不完全闭合有关。
J Vasc Surg Venous Lymphat Disord. 2024 Mar;12(2):101690. doi: 10.1016/j.jvsv.2023.09.004. Epub 2023 Oct 1.
4
Use of Polidocanol Endovenous Microfoam to Improve Hemodynamics and Symptomology in Patients with Challenging Clinical Presentations: A Case Series.使用聚多卡醇静脉微泡沫改善具有挑战性临床表现患者的血流动力学和症状:病例系列
Ann Vasc Surg. 2018 Oct;52:176-182. doi: 10.1016/j.avsg.2018.02.034. Epub 2018 Jun 19.
5
Adjunctive techniques to minimize thrombotic complications following microfoam sclerotherapy of saphenous trunks and tributaries.辅助技术以最小化微泡沫硬化治疗隐静脉主干和属支后的血栓并发症。
J Vasc Surg Venous Lymphat Disord. 2021 Jul;9(4):904-909. doi: 10.1016/j.jvsv.2020.11.015. Epub 2020 Nov 26.
6
Comparison of outcomes following polidocanol microfoam and radiofrequency ablation of incompetent thigh great and accessory saphenous veins.聚多卡醇微泡与射频消融治疗功能不全的大腿大隐静脉及属支的疗效比较。
J Vasc Surg Venous Lymphat Disord. 2023 Sep;11(5):916-920. doi: 10.1016/j.jvsv.2023.03.015. Epub 2023 Apr 7.
7
Results of polidocanol endovenous microfoam in clinical practice.聚多卡醇静脉内微泡沫的临床实践结果。
J Vasc Surg Venous Lymphat Disord. 2021 Jan;9(1):122-127. doi: 10.1016/j.jvsv.2020.04.015. Epub 2020 Apr 27.
8
Factors influencing recurrent varicose vein formation after radiofrequency thermal ablation for truncal reflux performed in two high-volume venous centers.影响在两家大容量静脉中心进行的主干反流射频热消融后复发性静脉曲张形成的因素。
J Vasc Surg Venous Lymphat Disord. 2024 Mar;12(2):101675. doi: 10.1016/j.jvsv.2023.08.014. Epub 2023 Sep 11.
9
Prospective randomized trial of antithrombotic strategies following great saphenous vein ablation using injectable polidocanol endovenous microfoam (Varithena).使用注射用聚多卡醇静脉微泡沫(Varithena)进行大隐静脉消融术后抗血栓形成策略的前瞻性随机试验
J Vasc Surg Venous Lymphat Disord. 2023 May;11(3):488-497.e4. doi: 10.1016/j.jvsv.2022.12.008. Epub 2022 Dec 31.
10
Favorable long-term results of endovenous laser ablation of great and small saphenous vein incompetence with a 1470-nm laser and radial fiber.1470nm 激光联合放射状光纤治疗大、小隐静脉功能不全的静脉腔内激光消融术的良好长期疗效。
J Vasc Surg Venous Lymphat Disord. 2021 Mar;9(2):352-360. doi: 10.1016/j.jvsv.2020.06.015. Epub 2020 Jun 27.

引用本文的文献

1
Comparative early outcomes following primary radiofrequency ablation and polidocanol microfoam ablation of symptomatic, incompetent small saphenous veins.有症状的、功能不全的小隐静脉原发性射频消融与聚多卡醇微泡沫消融后的早期疗效比较
J Vasc Surg Venous Lymphat Disord. 2025 Mar 20;13(4):102234. doi: 10.1016/j.jvsv.2025.102234.

本文引用的文献

1
Value and limitations of postoperative duplex scans after endovenous thermal ablation.静脉内热消融术后双功超声扫描的价值和局限性。
J Vasc Surg Venous Lymphat Disord. 2024 Jan;12(1):101672. doi: 10.1016/j.jvsv.2023.06.016. Epub 2023 Sep 9.
2
VIEW-VLU observational study of the effect of Varithena on wound healing in the treatment of venous leg ulcers.VIEW-VLU 观察性研究:观察 Varithena 在治疗静脉性腿部溃疡中的伤口愈合效果。
J Vasc Surg Venous Lymphat Disord. 2023 Jul;11(4):692-699.e1. doi: 10.1016/j.jvsv.2023.01.011. Epub 2023 Mar 25.
3
Sex Differences in Oral Anticoagulation Therapy in Patients Hospitalized With Atrial Fibrillation: A Nationwide Cohort Study.口服抗凝治疗与住院心房颤动患者的性别差异:一项全国性队列研究。
J Am Heart Assoc. 2023 Mar 7;12(5):e027211. doi: 10.1161/JAHA.122.027211. Epub 2023 Mar 2.
4
Endovenous microfoam ablation of below knee superficial truncal veins is safe and effective in patients with prior saphenous treatment across a wide range of CEAP classes.下肢浅静脉主干腔内微泡消融术治疗 CEAP 分级广泛的下肢浅静脉主干在既往大隐静脉处理后的患者中是安全且有效的。
J Vasc Surg Venous Lymphat Disord. 2022 Mar;10(2):390-394. doi: 10.1016/j.jvsv.2021.08.015. Epub 2021 Aug 30.
5
Adjunctive techniques to minimize thrombotic complications following microfoam sclerotherapy of saphenous trunks and tributaries.辅助技术以最小化微泡沫硬化治疗隐静脉主干和属支后的血栓并发症。
J Vasc Surg Venous Lymphat Disord. 2021 Jul;9(4):904-909. doi: 10.1016/j.jvsv.2020.11.015. Epub 2020 Nov 26.
6
Results of polidocanol endovenous microfoam in clinical practice.聚多卡醇静脉内微泡沫的临床实践结果。
J Vasc Surg Venous Lymphat Disord. 2021 Jan;9(1):122-127. doi: 10.1016/j.jvsv.2020.04.015. Epub 2020 Apr 27.
7
Prognosis of reflux of the below-knee great saphenous vein after surgical or endovenous treatment of reflux of the above-knee great saphenous vein.膝下大隐静脉反流在治疗膝上大隐静脉反流的手术或静脉内治疗后的预后。
J Vasc Surg Venous Lymphat Disord. 2020 Jul;8(4):629-633. doi: 10.1016/j.jvsv.2019.11.009. Epub 2020 Jan 9.
8
Recanalization After Endovenous Thermal Ablation.静脉内热消融术后再通
Ann Vasc Surg. 2018 Oct;52:158-162. doi: 10.1016/j.avsg.2018.03.017. Epub 2018 May 17.
9
The femoral vein diameter and its correlation with sex, age and body mass index - An anatomical parameter with clinical relevance.股静脉直径及其与性别、年龄和体重指数的相关性——一项具有临床意义的解剖学参数。
Phlebology. 2019 Feb;34(1):58-69. doi: 10.1177/0268355518772746. Epub 2018 Apr 27.
10
A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of Varithena® (polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence.一项多中心、随机、安慰剂对照研究,旨在评估聚多卡醇静脉微泡沫(1%)硬化剂(Varithena®)治疗伴有大隐静脉股静脉交界处功能不全的有症状、可见静脉曲张的疗效和安全性。
Phlebology. 2017 Apr;32(3):185-193. doi: 10.1177/0268355516635386. Epub 2016 Jul 9.

膝下聚多卡醇静脉内微泡沫消融治疗大隐静脉和小隐静脉后再通和再干预的相关因素。

Factors associated with recanalization and reintervention following below knee polidocanol endovenous microfoam ablation for great saphenous and small saphenous veins.

机构信息

Morristown Medical Center, Department of Surgery, Morristown, NJ.

Rowan-Virtua School of Osteopathic Medicine, Stratford, NJ.

出版信息

J Vasc Surg Venous Lymphat Disord. 2024 Sep;12(5):101886. doi: 10.1016/j.jvsv.2024.101886. Epub 2024 Apr 3.

DOI:10.1016/j.jvsv.2024.101886
PMID:38580208
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11523396/
Abstract

BACKGROUND

Polidocanol endovenous microfoam (PEM) has been used to treat lower extremity venous reflux for almost one decade with specific advantages for below knee (BK) truncal veins where thermal ablation poses a risk of injury to adjacent nerves. The current literature of the BK segment often examines short-term outcomes with modest sample sizes. We aim to identify factors associated with recanalization and reintervention in this subset of patients.

METHODS

We performed a retrospective study of a prospectively maintained database of patients from a single institution who underwent 1% PEM ablation for BK great saphenous vein (GSV) and small saphenous vein (SSV) reflux. Patients underwent duplex ultrasound (DU) within 7 days after injection, every 3 to 6 months for 1 year, and every 6 to 12 months thereafter. Patients with symptomatic recanalization underwent reintervention. The 26 patients lost to follow-up without DU after ablation were excluded. The factors associated with recanalization and reintervention were examined by multivariate and nonparametric analyses.

RESULTS

Between March 2018 and July 2023, 411 patients (166 male, 245 female) with 573 treated limbs (284 right, 289 left) met the study criteria. Of the 573 included limbs, 457 (79.8%) had undergone prior above knee saphenous ablations. A total of 554 BK GSV and 42 SSV ablations were performed. The most recent DU was performed at a mean of 231 ± 329 days. The overall recanalization rate was 10.6% (55 GSVs and 8 SSVs) at a mean follow-up of 104 ± 180 days. Comparing the closed and recanalized veins, we found no significant difference in age (P = .90), treated laterality (P = .14), patient body mass index (P = .59), preprocedural CEAP (clinical-etiology-anatomy-pathophysiology) score (P = .79), recanalization rate in GSVs vs SSVs (P = .06), or administered PEM volume (P = .24). The recanalized veins had significantly larger preprocedural diameters than the veins that remained closed (recanalized, 4.9 mm; closed, 4.3 mm; P = .001). Men had higher incidence of recanalization than women (men, 14.2%; women, 8%; P = .015). Anticoagulation use was associated with recanalization (odds ratio, 1.96; 95% confidence interval, 1.1-3.6; P = .03). Early recanalization at the first DU accounted for 31 failures (49.2%) and had a significantly lower administered PEM volume compared with later recanalization (early, 4 mL; late, 5 mL; P = .025). There were no significant differences between the 33 recanalized patients requiring reintervention (52.4%) and the 30 who did not. Twenty-four reinterventions were performed with PEM, 100% of which remained closed at a median of 160 days (interquartile range, 257 days).

CONCLUSIONS

PEM is successful for the treatment of BK GSV and SSV reflux with a closure rate of 89% at a mean of 231 days and shows promise as salvage therapy. Most cases of recanalization were noted in the early postprocedure period and were associated with a lower PEM volume. A larger vein diameter, male sex, and anticoagulation use are associated with higher rates of recanalization.

摘要

背景

聚多卡醇静脉内微泡(PEM)已用于治疗下肢静脉反流近十年,对于膝下(BK)主干静脉具有特定优势,因为热消融会对邻近神经造成损伤的风险。目前关于 BK 段的文献经常检查短期结果,样本量适中。我们旨在确定这组患者再通和再干预的相关因素。

方法

我们对一家机构前瞻性维护的数据库进行了回顾性研究,该数据库包括接受 1% PEM 消融治疗 BK 大隐静脉(GSV)和小隐静脉(SSV)反流的患者。患者在注射后 7 天内接受双功能超声(DU)检查,此后每 3 至 6 个月检查一次,持续 1 年,此后每 6 至 12 个月检查一次。有症状再通的患者进行再干预。在消融后无 DU 随访丢失的 26 例患者被排除在外。通过多变量和非参数分析检查与再通和再干预相关的因素。

结果

2018 年 3 月至 2023 年 7 月,411 名患者(166 名男性,245 名女性)共 573 条治疗肢体(284 条右侧,289 条左侧)符合研究标准。在纳入的 573 条肢体中,457 条(79.8%)曾接受过膝上隐静脉消融。共进行了 554 次 BK GSV 和 42 次 SSV 消融。最近一次 DU 检查平均在 231±329 天后进行。总的再通率为 10.6%(55 GSV 和 8 SSV),平均随访 104±180 天。比较闭合和再通静脉,我们发现年龄(P=0.90)、治疗侧(P=0.14)、患者体重指数(P=0.59)、术前 CEAP(临床-病因-解剖-病理生理学)评分(P=0.79)、GSV 与 SSV 之间的再通率(P=0.06)或给予的 PEM 体积(P=0.24)无显著差异。再通静脉的术前直径明显大于保持闭合的静脉(再通静脉,4.9mm;闭合静脉,4.3mm;P=0.001)。男性再通率高于女性(男性,14.2%;女性,8%;P=0.015)。抗凝治疗与再通相关(比值比,1.96;95%置信区间,1.1-3.6;P=0.03)。首次 DU 时早期再通占 31 例(49.2%),与后期再通相比,给予的 PEM 体积明显较低(早期,4ml;晚期,5ml;P=0.025)。需要再干预的 33 名再通患者(52.4%)与无需再干预的 30 名患者之间无显著差异。24 例再通患者接受了 PEM 治疗,中位数为 160 天(四分位距,257 天),其中 100%仍保持闭合。

结论

PEM 治疗 BK GSV 和 SSV 反流成功率高,平均 231 天后闭合率为 89%,并显示出作为补救治疗的潜力。大多数再通病例发生在术后早期,与 PEM 体积较低有关。静脉直径较大、男性和抗凝治疗与较高的再通率相关。